logo
ProjectForthcoming

Disease-responsive Synthetic Cell Therapy

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

This project aims to develop programmable, disease-responsive synthetic cells capable of sensing and adapting to pathological microenvironments—specifically hypoxia and acidity—by synthesizing and releasing therapeutic proteins on demand. Synthetic Cell Therapy, a novel class of precision medicine, will combine the adaptability of engineered living cell therapies with the precision and controllabi

Status
Prospective
Sector
Hospital
Location
United Kingdom
Updated
19 Nov 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Disease-responsive Synthetic Cell Therapy

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Disease-responsive Synthetic Cell Therapy” is an infrastructure initiative in the Hospital sector, located in United Kingdom. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

forthcoming

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

This project aims to develop programmable, disease-responsive synthetic cells capable of sensing and adapting to pathological microenvironments—specifically hypoxia and acidity—by synthesizing and releasing therapeutic proteins on demand. Synthetic Cell Therapy, a novel class of precision medicine, will combine the adaptability of engineered living cell therapies with the precision and controllability of synthetic drug delivery systems. By leveraging the safety, modularity, and programmability of bottom-up synthetic biology, the proposed work addresses key limitations of current therapeutics, including immune rejection and uncontrolled behavior (engineered cell therapy), poor targeting and premature drug release (synthetic drug delivery system). Two complementary strategies will be explored: (1) gene circuit–mediated therapeutic synthesis and release, and (2) physicochemical multi-stage drug release. WP1 will develop stimuli-responsive gene circuits for in situ transcription–translation of therapeutic proteins and pore-formers within microfluidic-generated synthetic cells, enabling real-time, stimuli-triggered therapeutic action. WP2 will engineer multi-compartmental synthetic cells with membrane lipids responsive to hypoxia and acidity, enabling graded, multi-stage release based on disease severity. Together, these approaches offer lifelike adaptive therapeutic behavior with spatial, temporal, and dosage control. This interdisciplinary proposal integrates synthetic biology, microfluidics, biomembrane engineering, and pharmaceutical sciences, aligning with MSCA priorities in excellence, interdisciplinary and frontier research. The project addresses unmet medical needs in cancer and neurodegeneration and advances next-generation, safe, and intelligent precision medicine platforms, contributing to the Horizon Europe goals of fostering innovation, strengthening Europe's research competitiveness, and improving healthcare outcomes.

Location

Country

United Kingdom (UK)

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital

Article published date

2026-09-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project